Hormone Receptor-Positive (HR+) Breast Cancer: Understanding Your Diagnosis

Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: October 2026

Quick Answer

Hormone receptor-positive (HR+) breast cancer means the cancer cells have proteins (receptors) that attach to estrogen or progesterone. [1] [2] These hormones act like “fuel” for the cancer. [2] Because this type depends on hormones, doctors can use specific medications to block those hormones, effectively “starving” the cancer cells and slowing or stopping their growth. [1] [2]

What the research says

• Receptor status can change, which is why re-testing matters. In a meta-analysis of 39 studies comparing primary breast tumors with paired distant metastases, 22.5% of ER-positive cancers (95% CI 16.4% to 30.0%) became ER-negative, while 21.5% of ER-negative cancers (95% CI 18.1% to 25.5%) became ER-positive. For the progesterone receptor, 49.4% of PR-positive cancers became PR-negative. The authors strongly encouraged reassessing receptor status in metastases (Schrijver et al., Journal of the National Cancer Institute, 2018). [4]

• Aromatase inhibitors lower recurrence more than tamoxifen in postmenopausal women. Pooling individual data on 31,920 postmenopausal women with ER-positive early breast cancer, aromatase inhibitors reduced recurrence by about 30% compared with tamoxifen while the treatments differed. Ten-year breast cancer mortality was 12.1% with 5 years of an aromatase inhibitor versus 14.2% with 5 years of tamoxifen (rate ratio 0.85, 95% CI 0.75 to 0.96). The trade-offs were more bone fractures (5-year risk 8.2% vs 5.5%) but fewer endometrial cancers (10-year incidence 0.4% vs 1.2%) (EBCTCG, The Lancet, 2015). [5]

• Recurrence risk continues for years after the first 5 years of therapy. In a meta-analysis of 88 trials with 62,923 women with ER-positive breast cancer who were disease-free after 5 years of endocrine therapy, recurrences occurred at a steady rate from year 5 to year 20. The risk of distant recurrence ranged from about 10% to 41%, depending on tumor size, lymph node involvement, and grade (Pan et al., New England Journal of Medicine, 2017). [6]

Key Takeaways

What Is Hormone Receptor-Positive Breast Cancer?

Hormone receptor-positive (HR+) breast cancer is defined by the presence of specific proteins on the surface of cancer cells. These proteins, called receptors, act as attachment points for hormones naturally produced in the body. When hormones like estrogen or progesterone bind to these receptors, they send signals to the cell to divide and multiply. [2]

This dependency on hormones is a distinguishing feature. Unlike hormone receptor-negative cancers, which grow independently of these signals, HR+ cancers require this hormonal “fuel.” Because they must wait for these signals to grow, they often progress at a slower pace than more aggressive, receptor-negative subtypes. [1] [2]

The Three Main Types of HR+ Status

A pathology report will specify which receptors are present. A cancer is considered positive when at least 1% of the cells in a sample have receptors. [2]

• Estrogen Receptor-Positive (ER+): The cells have receptors for estrogen. This is the most common pattern, found in at least two-thirds of breast cancers. [2]

• Progesterone Receptor-Positive (PR+): The cells have receptors for progesterone. This is the least common pattern and is rarely found without ER+ status. [2]

• Double Positive (ER/PR+): The cells have receptors for both hormones, which is very common in HR+ diagnoses and is found in more than half of breast cancers. [2]

Symptoms and Identifying the Condition

HR+ breast cancer does not typically present with unique symptoms that distinguish it from other forms of breast cancer. [2] The hormone status is a microscopic characteristic rather than a visible one. [2]

Causes and Risk Factors

Breast cancer cells develop receptors because they originate from normal breast cells, which naturally have these receptors to respond to reproductive cycles. [2] While the exact trigger for the initial mutation is often unknown, certain factors can influence the risk of developing hormone-dependent tumors.

High levels of estrogen in the body over a long period are closely linked to HR+ breast cancer risk. [3] This can be influenced by:

• Reproductive History: Starting menstruation early or reaching menopause later. [3]

• Hormone Therapy: Long-term use of combined hormone replacement therapy (HRT). [2] [3]

• Lifestyle Factors: Obesity, which increases estrogen production in fat tissue. [2]

• Pregnancy History: Having a first pregnancy at an older age or never having a full-term pregnancy.

Diagnosis and Pathology Testing

The only way to confirm hormone receptor status is through a laboratory analysis of a tissue sample. [2] This is typically done after a biopsy or surgery. [1]

1. Biopsy: A small sample of the tumor is removed. [2]

2. Immunohistochemistry (IHC) Test: Pathologists use special stains to identify the presence of ER and PR proteins. [1] [2]

3. Pathology Report: The results are recorded as a percentage of cells that stain positive. If 1% or more of the cells have receptors, the cancer is considered positive. [2] The American Cancer Society describes 1% to 10% as “low positive” and more than 10% as “positive,” and hormone therapy is offered when more than 1% of cells have receptors. [1]

Management and Targeted Treatment

The primary advantage of an HR+ diagnosis is the availability of hormone therapy, also known as endocrine therapy. These treatments are designed to “starve” the cancer by cutting off its hormone supply. [2]

Common Hormone Therapy Approaches

Comprehensive Care Plan

Hormone therapy is often used in combination with other standard treatments to ensure the best outcome. This may include surgery (lumpectomy or mastectomy) to remove the primary tumor, followed by radiation or chemotherapy if there is a risk of the cancer spreading. [2] [3] In some cases, targeted therapies that work alongside hormone medications are used to overcome treatment resistance.

Outlook and Long-Term Recovery

Individuals with HR+ breast cancer generally have a more favorable long-term outlook compared to those with receptor-negative types. [1] [2] The slow-growing nature of the disease and the effectiveness of hormone therapies contribute to high survival rates, especially when the cancer is caught in early stages. These cancers can sometimes come back many years after treatment, which is why long-term hormone therapy and regular follow-up matter. [1] [6]

It is important to note that hormone receptor status can occasionally change. If the cancer recurs or spreads, doctors often re-test the tissue, as a change in status would require a different treatment strategy. [2] [4]

Conclusion

A diagnosis of hormone receptor-positive breast cancer provides a clear pathway for targeted treatment. By understanding how hormones influence the growth of the disease, healthcare teams can utilize effective therapies to manage and overcome the condition. Early detection and adherence to long-term care plans remain the most effective tools for ensuring a positive outcome.

Frequently Asked Questions

What does HR+ mean in breast cancer?

HR+ means the cancer cells have receptors for estrogen, progesterone, or both. [1] [2]

Is HR+ breast cancer curable?

Many cases, especially those found early, are treated with the goal of cure. HR+ cancer can sometimes come back many years after treatment, which is why hormone therapy often continues for several years. [1]

Does HR+ breast cancer grow fast?

No. It generally grows more slowly than hormone receptor-negative types. [1] [2]

What is the most common treatment for HR+ breast cancer?

Hormone therapy is the cornerstone of treatment, usually alongside surgery. [2]

How long do you take hormone therapy?

Hormone therapy is often taken for 5 to 10 years to help prevent recurrence. Your oncologist will tailor the length to your situation.

Can men get HR+ breast cancer?

Yes. Male breast cancer can be hormone receptor-positive [2], and most male breast cancers are.

What is an IHC test?

A lab test used to identify proteins like hormone receptors in cancer cells. [1]

What is the difference between ER+ and PR+?

ER+ cancers have receptors that bind estrogen; PR+ cancers have receptors that bind progesterone. [2]

Does obesity affect HR+ breast cancer?

Yes. Fat tissue produces estrogen, which can increase risk. [2]

Can I get HR+ breast cancer if I don't have a family history?

Yes. Most cases occur in people without a strong family history.

Is hormone therapy the same as chemotherapy?

No. It targets specific hormones rather than killing all fast-growing cells.

What are the side effects of hormone therapy?

Common effects include hot flashes, joint pain, fatigue, and mood changes. Aromatase inhibitors can also thin the bones, so your care team may monitor bone health. [5] Tamoxifen carries a warning for uncommon but serious risks, including blood clots, stroke and cancer of the uterus, so report leg swelling, chest pain or shortness of breath, sudden weakness, or unusual vaginal bleeding right away.

Does HR+ status affect surgery options?

No. Surgery is usually based on the size and location of the tumor.

What is a pathology report?

A document from a lab that describes the characteristics of your cancer.

Can hormone receptor status change?

Yes. In a meta-analysis of 39 studies, about 22% of ER-positive cancers became ER-negative in distant metastases, and about 21% of ER-negative cancers became ER-positive. [4] For this reason, doctors often re-test the tissue if the cancer returns or spreads. [2] [4]

Why do I need to take pills for 5 years or more?

To keep the effect of estrogen low and prevent any remaining cancer cells from growing. HR+ cancers can recur years after treatment. [1] [6]

What are aromatase inhibitors?

Drugs that stop the body from making estrogen after menopause. [2]

What is Tamoxifen?

A common SERM that blocks estrogen receptors in breast tissue.

Can HR+ breast cancer be stage 4?

Yes. Stage refers to how far the cancer has spread, while HR+ refers to the type of cancer cell.

Is HR+ better than HR-?

HR+ breast cancer generally has a better short-term outlook because there are more treatment options, although HR+ cancers can sometimes return many years later. [1]

Does HR+ breast cancer spread to bones?

HR+ breast cancer can. Breast cancer may spread to the bones, lungs, liver, and brain [3], and treatment aims to lower that risk.

What is ovarian suppression?

Using medicine or surgery to stop the ovaries from making estrogen. [2]

Can I still get pregnant after HR+ treatment?

Fertility after HR+ treatment depends on the specific treatments used. Discuss fertility with your doctor, ideally before treatment starts.

Does HR+ breast cancer respond to radiation?

Yes. Radiation is often used after surgery for HR+ tumors.

What is the survival rate for HR+ breast cancer?

Survival rates are very high, particularly for early-stage disease. Cleveland Clinic cites National Cancer Institute data showing more than 90% of females were alive five years after an ER-positive diagnosis. [3]

How do hormones “fuel” cancer?

Hormones bind to receptors and trigger the cell's growth cycle.

What percentage makes a tumor “positive”?

At least 1% of cells must show receptors. [2] The American Cancer Society calls 1% to 10% “low positive” and more than 10% “positive,” and offers hormone therapy when more than 1% of cells have receptors. [1]

Is triple-positive breast cancer HR+?

Yes. It is positive for ER, PR, and HER2. [1]

What if my cancer is ER+ but PR-?

Cancer that is ER+ but PR- is still treated as hormone receptor-positive. [1]

Do I need chemotherapy for HR+ cancer?

Not always. It depends on the stage and other risk factors.

What is an Oncotype DX test?

A genomic test often used for HR+ cancer to see if chemotherapy is needed.

Can diet help HR+ breast cancer?

A healthy diet supports recovery, but it doesn't replace medical treatment.

Does exercise lower recurrence risk?

Regular physical activity is linked to a lower risk of recurrence and can help with weight and overall health.

What is endocrine therapy?

Another name for hormone therapy.

Are there natural alternatives to hormone therapy?

No natural remedy has been shown to replace medical hormone therapy. Supplements and herbal products can interact with treatment, so tell your care team before using them.

What is a lumpectomy?

Surgery to remove only the tumor and a small margin of healthy tissue.

What is a mastectomy?

Surgery to remove the entire breast.

How often should I have follow-ups?

Often every 3 to 6 months in the first few years, then less often. Your care team will set the schedule.

Can HR+ breast cancer be prevented?

Risk can be lowered through lifestyle, but it cannot be entirely prevented.

Does HR+ status affect the type of reconstruction?

No. Reconstruction is a separate surgical decision.

Is HR+ cancer hereditary?

Some cases are linked to genes like BRCA, but most are not.

What is the HER2 protein?

Another protein often tested alongside hormone receptors.

What is “luminal A” breast cancer?

A common subtype that is HR+ and HER2-negative.

What is “luminal B” breast cancer?

An HR+ subtype that may grow slightly faster than luminal A.

Does HR+ cancer cause nipple discharge?

HR+ cancer can, similar to other breast cancer types.

Can stress cause HR+ breast cancer?

There is no direct evidence that stress causes cancer.

Is HR+ breast cancer more common after menopause?

Yes. The majority of postmenopausal breast cancers are HR+.

What if I miss a dose of hormone therapy?

Do not double up. Take your next dose as scheduled and let your care team know so they can advise you.

Does HR+ cancer affect both breasts?

Usually it starts in one, but it can occasionally be bilateral.

Where can I find support for HR+ breast cancer?

Many organizations offer support groups and resources for patients. In the U.S., the American Cancer Society runs a 24/7 helpline at 1-800-227-2345.

Related Reading

• Aromatase Inhibitors: Hormone Therapy for Breast Cancer

• Understanding Menopause: Stages, Symptoms, and Management

Immunohistochemistry (IHC): What It Is, How It Works and What Results Mean explains the antibody staining test that identifies cancer type and treatment targets.

References

1. American Cancer Society. Breast Cancer Hormone Receptor Status. American Cancer Society. Last revised July 23, 2026. https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-hormone-receptor-status.html

2. Cleveland Clinic. Hormone Receptor-Positive (HR+) Breast Cancer: Care & Outlook. Cleveland Clinic. Last updated March 3, 2026. https://my.clevelandclinic.org/health/diseases/hormone-receptor-positive-breast-cancer

3. Cleveland Clinic. ER-Positive Breast Cancer: Symptoms, Treatment & Prognosis. Cleveland Clinic. Last updated February 2, 2024. https://my.clevelandclinic.org/health/diseases/er-positive-breast-cancer

4. Schrijver WAME, Suijkerbuijk KPM, van Gils CH, et al. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis. Journal of the National Cancer Institute. 2018;110(6):568-580. PMID 29315431. https://doi.org/10.1093/jnci/djx273

5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. The Lancet. 2015;386(10001):1341-1352. PMID 26211827. https://doi.org/10.1016/S0140-6736(15)61074-1

6. Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. New England Journal of Medicine. 2017;377(19):1836-1846. PMID 29117498. https://doi.org/10.1056/NEJMoa1701830

Disclaimer

This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.